•
Sep 30, 2021

Aflac Q3 2021 Earnings Report

Aflac reported third quarter results with net earnings of $888 million and adjusted earnings per diluted share of $1.53.

Key Takeaways

Aflac Incorporated reported third quarter net earnings of $888 million, or $1.32 per diluted share. Total revenues were $5.2 billion, compared to $5.7 billion in the same quarter of the previous year. Adjusted earnings per diluted share increased by 10.1% to $1.53.

Total revenues were $5.2 billion, compared with $5.7 billion in the third quarter of 2020.

Net earnings were $888 million, or $1.32 per diluted share.

Adjusted earnings per diluted share increased 10.1% to $1.53.

Aflac Japan's pretax adjusted earnings increased 30.7% to $976 million.

Total Revenue
$5.24B
Previous year: $5.67B
-7.6%
EPS
$1.53
Previous year: $1.39
+10.1%
Gross Profit
$5.24B
Previous year: $5.67B
-7.6%
Cash and Equivalents
$146B
Previous year: $146B
-0.1%
Total Assets
$161B
Previous year: $161B
-0.2%

Aflac

Aflac

Aflac Revenue by Segment

Aflac Revenue by Geographic Location

Forward Guidance

Aflac expects small businesses to continue in recovery mode through the rest of the year, while larger businesses have shown better potential for sales in the fourth quarter. The company remains committed to prudent liquidity and capital management and will continue to tactically repurchase shares.

Positive Outlook

  • September launch of the new nursing care product was off to a promising start.
  • Ability to meet face-to-face with customers appears to be improving gradually.
  • Larger businesses have been more resilient and have shown better potential for sales in the fourth quarter.
  • Committed to prudent liquidity and capital management.
  • Continue to tactically repurchase shares.

Challenges Ahead

  • Pandemic conditions were more challenging in Japan.
  • Widespread states of emergency persisted through the third quarter in Japan.
  • Small businesses are still in recovery mode.
  • Third quarter sales were essentially flat year over year in Japan.
  • New nursing care product will take time to have a measurable impact on overall sales outlook.